EPCAM and neoplasm: The synergistic effects of regorafenib and CAR NK-92 cells, which recognize EpCAM+ CRC cells, and release cytokines, such as IFN-γ, perforin, and granzyme B, while reducing tumor xenografts in mice, were observed [80].